What Happened
The Section 232 tariff deadline covering 17 major drugmakers has passed, Pharmaceutical Commerce reported on 3 August 2026. Section 232 is the US statute permitting tariffs on imports judged to affect national security. Pharmaceutical Commerce has published a question and answer briefing setting out what pharmaceutical supply chain teams need to know now the date of 31 July has gone by. The summary available does not name the 17 companies, state final tariff rates, or confirm an effective date for collection.
Published: Mon, 03 Aug 2026 Source: Pharmaceutical Commerce
What UK Pharmaceutical Exporters Should Check Now
The immediate exposure for UK exporters is contractual, not operational. Where you sell to a US buyer on DDP terms under Incoterms 2020, you are the party liable for US import duty, so any Section 232 tariff lands on your margin rather than the customer’s. Where you sell DAP or FCA, the buyer carries it. Review live contracts and quotations for tariff-cost clauses before the next consignment books, because pricing agreed before 31 July may no longer cover the delivered cost.
Classification and valuation decide the size of any bill. The duty applies to the declared customs value on the US entry, so first-sale arrangements, transfer pricing between group entities and the treatment of freight and insurance charges all change the exposure. Finished dose forms, bulk active ingredient and packaging components sit under different headings, and misclassifying any of them is a compliance risk as well as a cost risk. Most UK pharmaceutical consignments to the US move by air freight on temperature-controlled services.
Watch for the official notices rather than the commentary. Rates, effective dates and any product exclusions come from published US federal notices, and until those appear, forecasts of the rate are analyst expectation rather than confirmed fact. In the meantime, review whether goods can be held under bonded warehousing in the UK to delay duty points on inbound flows, and check whether your CDS declarations and EORI records reflect the entity that will actually be invoiced.
Key Takeaway
The deadline passing changes commercial risk before it changes freight operations. Check who bears import duty under your Incoterms 2020 terms, confirm the declared customs value basis, and hold pricing decisions until the official US notice sets out rates, effective dates and any exclusions.
Market Impact
Tariff deadlines in pharmaceutical trade tend to pull inventory forward. Manufacturers commonly build US stock ahead of a duty point, which lifts airfreight demand and rates on transatlantic lanes for a short period, then leaves them soft once positioning is complete. UK exporters booking temperature-controlled capacity into US gateways should expect competition for equipment during any pull-forward window, and should book validated packaging further ahead than usual rather than relying on short-notice availability.
The longer-run effect falls on network design. If tariffs make US-bound finished goods more expensive, some owners will ship bulk active ingredient for finishing inside the US instead, which changes the commodity code, the packaging specification and often the mode. That shift moves volume away from small, high-value air consignments towards larger, less time-critical movements. Whether that happens depends entirely on the published rates, which Pharmaceutical Commerce has not yet reported as finalised.
Source: https://www.pharmaceuticalcommerce.com/view/faq-pharmas-july-31-tariff-deadline-has-passed-now-what-
